$EQ News

Last published 6d ago

6d agoEQEquillium to Participate in Upcoming Investor ConferencesGlobeNewswireLA JOLLA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat serious autoimmune and inflammatory disorders, today announced that
2w agoEQEquillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504GlobeNewswireTopline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of $20 million in
1mo agoEQEquillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology ConferenceGlobeNewswireLA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new
1mo agoEQSTIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - EQUILLIUM INCEarnings Call TranscriptsGood afternoon now, I guess on the East Coast side. Appreciate you joining us for the next Fireside Chat with Aquilium CSO, Stephen Connolly, to walk us through the story here. Maybe I'll kick it over to Stephen to sort
1mo agoEQEquillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation ForumGlobeNewswireLA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that
2mo agoEQEquillium to Participate in Upcoming Investor ConferencesGlobeNewswireLA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that
3mo agoEQEquillium Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswirePhase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA
5mo agoEQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June
5mo agoEQEquillium to Participate in the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireLA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that
5mo agoEQEquillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 AxisGlobeNewswireLA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it will host a
6mo agoEQEquillium Reports First Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswirePhase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph.D., as Chief Development Officer to lead clinical
6mo agoEQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on May 1,
6mo agoEQEquillium to Participate in Oppenheimer's 2026 Innovation on the Island EventGlobeNewswireLA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that
7mo agoEQEquillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of ImmunologistsGlobeNewswireLA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new
7mo agoEQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on
7mo agoEQEquillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical HighlightsGlobeNewswireInitiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund
8mo agoEQEquillium Announces $35 Million Financing with RA Capital ManagementGlobeNewswireCapital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA JOLLA, Calif., March
8mo agoEQEquillium to Participate in the Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswireLA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that
9mo agoEQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on
11mo agoEQEquillium to Participate in Upcoming Investor ConferencesGlobeNewswireLA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe
12mo agoEQEquillium Reports Third Quarter 2025 Financial Results and Provides Operational UpdateGlobeNewswireClosed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal
1y agoEQEquillium to Participate in Upcoming Investor ConferencesGlobeNewswireLA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe
1y agoEQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireLA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on
1y agoEQEquillium to Host Ulcerative Colitis KOL Event on November 5, 2025GlobeNewswireLA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe
1y agoEQEquillium Announces Leadership and Corporate UpdatesGlobeNewswireLA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe
1y agoEQNeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs AdvisorGlobeNewswireSAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics,
1y agoEQEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireEquillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on August 29, 2025, the Compensation Committee of Equillium's
1y agoEQEquillium to Participate in the Cantor Global Healthcare Conference 2025Business WireEquillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Cantor
1y agoEQEquillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the ClinicBusiness WireFinancing led by ADAR1 Capital Management and Janus Henderson Investors $30 million up front with the potential to receive an additional $20 million at clinical study initiation Phase 1 clinical study initiation
1y agoEQEquillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve StrategyBusiness WireEquillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced a strategic expansion to integrate a cryptocurrency treasury
1y agoEQEquillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of ImmunologistsBusiness WireEQ504 protects against gut damage in a mouse model of ulcerative colitis EQ504 increases Treg stability and function while suppressing pathogenic Th17 responses EQ504 promotes healing of intestinal epithelial cells by
1y agoEQEquillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504Business WireEQ504 targets the aryl hydrocarbon receptor, a clinically validated pathway in the treatment of both skin and gastrointestinal diseases EQ504 has a unique, multi-modal, non-immunosuppressive mechanism of action that is
1y agoEQEquillium Announces Feedback from the U.S. Food and Drug AdministrationBusiness WireEquillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced
1y agoEQEquillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical HighlightsBusiness WireAnnounced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease Breakthrough Therapy designation and meeting request to discuss potential for Accelerated Approval submitted to FDA,
1y agoEQEquillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host DiseaseBusiness WireTreatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in
1y agoEQEquillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative ColitisBusiness WireItolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo Itolizumab achieved key secondary endpoint of
1y agoEQEquillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical UpdatesBusiness WireEquillium retains rights to itolizumab following substantial funding from Ono partnership Evaluating accelerating Phase 3 EQUATOR study in aGVHD to completion in Q1 2025 Phase 2 ulcerative colitis study recently
1y agoEQEquillium to Present at the Stifel Healthcare ConferenceBusiness WireEquillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced
1y agoEQEquillium Announces Poster Presentation at the Society for Immunotherapy of CancerBusiness WireDual and synergistic signaling of IL-15 and IL-21 robustly augments NK and CD8 T cell responses Highlights importance of dual inhibition or activation for therapeutic approaches Equillium Inc. (NASDAQ:EQ), a
2y agoEQEquillium Maintains Rights to Itolizumab Following Ono PartnershipBusiness WireOno Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study
2y agoEQEquillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of CancerBusiness WireCombination of IL-15 and IL-21 robustly augments NK and CD8 T cell activity Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel
2y agoEQEquillium to Present at the Stifel Virtual Inflammation & Immunology SummitBusiness WireEquillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced
2y agoEQEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireEquillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on August 30, 2024, the
2y agoEQEquillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor ConferenceBusiness WireEquillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced
2y agoEQEquillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical HighlightsBusiness Wire$33.3 million cash balance at the end of Q2 2024, representing a $1.0 million increase from the end of Q1 2024 Triggered Ono option exercise period to acquire Equillium's rights to itolizumab, decision expected before
2y agoEQEquillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host DiseaseBusiness WireThe Independent Data Monitoring Committee (IDMC) recommended continuation of the clinical trial based on safety assessment and pre-determined futility and efficacy stopping boundaries The results of the IDMC review
2y agoEQEquillium Announces Second Quarter 2024 Estimated Cash and Investments BalanceBusiness WireQ2 ending cash, cash equivalents and short-term investments totaled approximately $33.3 million, an increase of approximately $1.0 million compared to the amount at the end of Q1 Equillium, Inc. (NASDAQ:EQ), a
2y agoEQEquillium to Participate in Upcoming Investor ConferencesBusiness WireEquillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the
2y agoEQEquillium to be included in the Russell Microcap® IndexBusiness WireEquillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell
2y agoEQEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireEquillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on May 31, 2024, the Compensation